PENGARUH PENGGUNAAN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR DAN ANGIOTENSIN RECEPTOR BLOCKER TERHADAP MORTALITAS PASIEN COVID-19 DENGAN KOMORBIDITAS PENYAKIT KARDIOVASKULAR TINJAUAN SISTEMATIS

Aulia Setya Nurrachmah, . (2021) PENGARUH PENGGUNAAN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR DAN ANGIOTENSIN RECEPTOR BLOCKER TERHADAP MORTALITAS PASIEN COVID-19 DENGAN KOMORBIDITAS PENYAKIT KARDIOVASKULAR TINJAUAN SISTEMATIS. Skripsi thesis, Universitas Pembangunan Nasional Veteran Jakarta.

[img] Text
ABSTRAK.pdf
Download (89kB)
[img] Text
AWAL.pdf
Download (742kB)
[img] Text
BAB 1.pdf
Download (110kB)
[img] Text
BAB 2.pdf
Restricted to Repository UPNVJ Only
Download (360kB)
[img] Text
BAB 3.pdf
Restricted to Repository UPNVJ Only
Download (117kB)
[img] Text
BAB 4.pdf
Restricted to Repository UPNVJ Only
Download (236kB)
[img] Text
BAB 5.pdf
Download (75kB)
[img] Text
DAFTAR PUSTAKA.pdf
Download (196kB)
[img] Text
RIWAYAT HIDUP.pdf
Restricted to Repository UPNVJ Only
Download (40kB)
[img] Text
LAMPIRAN.pdf
Restricted to Repository UPNVJ Only
Download (1MB)
[img] Text
ARTIKEL KI.pdf
Restricted to Repository staff only
Download (462kB)

Abstract

Background: COVID-19 has a high prevalence in patients with underlying comorbidity, such as cardiovascular disease. Angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy in COVID-19 patients with cardiovascular disease comorbidity gives rise to a controversy for ACEI and ARB could upregulate angiotensin-converting enzyme 2 (ACE2) expression in a previous study in animals. ACE2 is considered a receptor for SARS-CoV-2, suggesting that ACEI and ARB consumption would worsen the patient’s condition. This systematic review aims to analyze the effects of ACEI and ARB on the mortality of COVID-19 patients with cardiovascular disease comorbidity. Methods: This systematic review was conducted from July to August 20, 2020 for the literature collection. The literature were collected from PubMed, Google Scholar, and Science Direct, according to Preferred Reporting Items for Systematic Reviews and Meta-analysis Protocols (PRISMA-P). Results: There were eight data obtained. Three literatures resulted in lower mortality in COVID-19 patients with cardiovascular disease comorbidity who consumed ACEI/ARB. Five literatures concluded that there was no significant difference between COVID-19 patients who consumed ACEI/ARB and who did not. Conclusion: The mortality in COVID-19 patients with cardiovascular disease comorbidity who consumed ACEI/ARB is lower, according to three literatures, therefore, the therapy using ACEI/ARB should be continued because it is more beneficial to keep consuming ACEI/ARB than to stop consuming them.

Item Type: Thesis (Skripsi)
Additional Information: [No. Panggil: 1710211059] [Pembimbing: Hany Yusmaini] [Penguji 1: Ryan Herardi]
Uncontrolled Keywords: COVID-19, ARB, ACEI, mortality, cardiovascular
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Fakultas Kedokteran > Program Studi Kedokteran (S1)
Depositing User: Aulia Setya Nurrachmah
Date Deposited: 12 Mar 2021 08:48
Last Modified: 30 Jun 2021 03:55
URI: http://repository.upnvj.ac.id/id/eprint/9179

Actions (login required)

View Item View Item